BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition  

作　　者：Yu Meng Hui-Yan Sun Yi He Qian Zhou Yi-Huang Liu Hui Su Ming-Zhu Yin Fu-Rong Zeng Xiang Chen Guang-Tong Deng 

机构地区：[1]Department of Dermatology,Xiangya Hospital,Central South University,Changsha 410008,China [2]National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology,Changsha 410008,China [3]Furong Laboratory,Changsha 410008,China [4]Hunan Key Laboratory of Skin Cancer and Psoriasis,Hunan Engineering Research Center of Skin Health and Disease,Xiangya Hospital,Central South University,Changsha 410008,China [5]National Clinical Research Center for Geriatric Disorders,Xiangya Hospital,Changsha 410008,China [6]Department of Breast Reconstruction,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300202,China [7]Department of Oncology,Xiangya Hospital,Central South University,Changsha 410008,China

出　　处：《Military Medical Research》2024年第4期620-624,共5页军事医学研究（英文版）

基　　金：This work was supported by grants from the National Natural Science Foundation of China(82103183,82102803,82272849);the Natural Science Foundation of Hunan Province(2022JJ40767,2021JJ40976);the Natural Science Fund for Outstanding Youths in Hunan Province(2023JJ20093);the National Key Research and Development Program(2022YFC2504700).

摘　　要：Dear Editor,Ferroptosis,an iron-dependent form of cell death driven by overwhelming lipid peroxidation,represents a vulnerability in cancers,and therapeutic strategies to further potentiate ferroptosis hold great potential for melanoma treatment.

关 键 词：MELANOMA Bromodomain and extra terminal domain(BET)inhibitor Ferroptosis Cell death AKR1C2 IMMUNOTHERAPY 

分 类 号：R739.5[医药卫生—肿瘤]